“Adverse Events of Special Interest in Patients With Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s67, https://doi.org/10.25251/skin.4.supp.66.